Lineagen, Inc.: Series A $5M

Posted in I - Series A, Q - 3Q10, R - ROCKY MOUNTAIN, X - Autism, X - Device (Diagnostic), XX - UT

Lineagen (Salt Lake City, UT) a development stage content-based biomarker discovery company focused on diagnostic tests for autism, multiple sclerosis and COPD, closed a $5M Series A, bringing the total round to $10.8M. Participants include PrairieGold Venture Partners, vSpring Capital, Sanderling Ventures and Mesa Verde Venture Partners.

Jul

2010

SynapDx Corp.: Series A $9M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Autism, X - Device (Diagnostic), XX - MA

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

Nov

2009

Seaside Therapeutics, LLC: Series A $30M

Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - Autism, X - FragileX Syndrome, XX - MA

Seaside Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on autism and Fragile X syndrome, closed a $30M Series A financing. Participants were not identified.

to top of page...